SEC Comment Letter for AIM ImmunoTech Inc. (AIM) (CIK 0000946644) (AIM) — Oct 11, 2017
AIM ImmunoTech Inc. (AIM) (CIK 0000946644)
Date: Oct. 11, 2017 · CIK: 0000946644 · Accession: 0000000000-17-035908
AI Filing Summary & Sentiment
Reasoning
Letter
October 10, 2017 Thomas K. Equels Chief Executive Officer Hemispherx Biopharma, Inc. 1617 JFK Boulevard Philadelphia, PA 19103 Hemispherx Biopharma, Inc. Registration Statement on Form S-3 Filed September 29, 2017 File No. 333-220756Re: Dear Mr. Equels: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at (202) 551-5019 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Richard Feiner, Esq.
Show Raw Text
October 10, 2017 Thomas K. Equels Chief Executive Officer Hemispherx Biopharma, Inc. 1617 JFK Boulevard Philadelphia, PA 19103 Hemispherx Biopharma, Inc. Registration Statement on Form S-3 Filed September 29, 2017 File No. 333-220756Re: Dear Mr. Equels: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at (202) 551-5019 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Richard Feiner, Esq.